Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance

European Journal of Internal Medicine

Volumn 23, Issue 1, 2012, Pages 48-53

  Wang, Xiao Dong ^a   Zhang, Dai Fu ^a   Liu, Xue Bo ^a   Lai, Yan ^a   Qi, Wei Gang ^a   Luo, Yu ^a   Hu, Bo ^a   Yao, Yi An ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

ABCB1; Clopidogrel; Vasodilator stimulated phosphoprotein

Indexed keywords

CLOPIDOGREL; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ALLELE; ARTICLE; BLEEDING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POLYMERASE CHAIN REACTION; SILENT MYOCARDIAL ISCHEMIA; STATISTICAL PARAMETERS; THROMBOCYTE ACTIVATION; VASODILATOR STIMULATED PHOSPHOPROTEIN INDEX;

AGED; ALLELES; BLOOD PLATELETS; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MUTATION; P-GLYCOPROTEIN; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 83555174775     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2011.07.016     Document Type: Article

References (31)

1. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, and M.K. Natarajan Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533 (Pubitemid 32772726)
2. W. Hochholzer, D. Trenk, D. Frundi, P. Blanke, B. Fischer, and K. Andris Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention Circulation 111 2005 2560 2564 (Pubitemid 40740853)
3. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913 (Pubitemid 36736631)
4. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251 (Pubitemid 40094733)
5. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, M. Sabaté, and C. Fernández PIA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation Blood Coagul Fibrinolysis 15 2004 89 93 (Pubitemid 38534691)
6. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramírez, U. Cavallari, and E. Trabetti Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel Arterioscler Thromb Vasc Biol 26 2006 1895 1900 (Pubitemid 44305347)
7. J.T. Brandt, S.L. Close, S.J. Iturria, C.D. Payne, N.A. Farid, and C.S. Ernest II Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436 (Pubitemid 350154353)
8. P. Fontana, A. Dupont, S. Gandrille, C. Bachelot-Loza, J.L. Reny, and M. Aiach Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects Circulation 108 2003 989 995 (Pubitemid 37048230)
9. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, and R. Paniccia Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12 G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics 17 2007 1057 1064 (Pubitemid 351339490)
10. J.S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, and C. Goyenvalle Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247 (Pubitemid 44497506)
11. D. Taubert, N. von Beckerath, G. Grimberg, A. Lazar, N. Jung, and T. Goeser Impact of P-glycoprotein on clopidogrel absorption Clin Pharmacol Ther 80 2006 486 501 (Pubitemid 44767878)
12. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, and C.M. Valina Cytochrome P450 2C19 681 G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934 (Pubitemid 351636443)
13. W. Hochholzer, D. Trenk, M.F. Fromm, C.M. Valina, C. Stratz, and H.P. Bestehorn Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
14. C. Frere, T. Cuisset, P.E. Morange, J. Quilici, L. Camoin-Jau, and N. Saut Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am J Cardiol 101 2008 1088 1093
15. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome P-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
16. C. Varenhorst, S. James, D. Erlinge, J.T. Brandt, O.O. Braun, and M. Man Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur Heart J 30 2009 1744 1752
17. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, J.R. Walker, and T. Simon Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
18. L. Wallentin, S. James, R.F. Storey, M. Armstrong, B.J. Barratt, and J. Horrow Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
19. F.G. Kushner, M. Hand, S.C. Smith Jr., S.B. King III, J.L. Anderson, and E.M. Antman 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 2241
20. L. Bonello, F. Paganelli, M. Arpin-Bornet, P. Auquier, J. Sampol, and F. Dignat-George Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events J Thromb Haemost 5 2007 1630 1636 (Pubitemid 47091403)
21. A.K. Rao, C. Pratt, A. Berke, A. Jaffe, I. Ockene, and T.L. Schreiber Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1988 1 11 (Pubitemid 18029027)
22. M.B. Leon, D.S. Baim, J.J. Popma, P.C. Gordon, D.E. Cutlip, and K.K. Ho A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting N Engl J Med 339 1998 1665 1671 (Pubitemid 28550691)
23. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Méneveau Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
24. L. Bonello, S. Armero, O. Ait Mokhtar, J. Mancini, P. Aldebert, and N. Saut Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2 C19*2 loss of function polymorphism J Am Coll Cardiol 56 2010 1630 1636
25. P. Barragan, J.L. Bouvier, P.O. Roquebert, G. Macaluso, P. Commeau, and B. Comet Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation Catheter Cardiovasc Interv 59 2003 295 302 (Pubitemid 36792384)
26. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, L. Nait-Saidi, and J. Carvajal Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting J Am Coll Cardiol 48 2006 1339 1345 (Pubitemid 44436814)
27. W.A. Schumacher, J.S. Bostwick, M.L. Ogletree, A.B. Stewart, T.E. Steinbacher, and J. Hua Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats J Pharmacol Exp Ther 322 2007 369 377 (Pubitemid 46956346)
28. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, and R. Becker Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP J Am Coll Cardiol 56 2010 919 933
29. L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, and O. Wittenberg Adjusted clopidogrel loading doses according to vasodilator- stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411 (Pubitemid 351447314)
30. L. Bonello, L. Camoin-Jau, S. Armero, O. Com, S. Arques, and C. Burignat-Bonello Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis Am J Cardiol 103 2009 5 10
31. X.D. Wang, D.F. Zhang, S.W. Zhuang, and Y. Lai Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance Clin Cardiol 34 2011 332 338